Payload Information
General Information of This Payload
| Payload ID | PAY0ERORN |
|||||
|---|---|---|---|---|---|---|
| Name | SMol006 |
|||||
| Synonyms |
Smol006
Click to Show/Hide
|
|||||
| Target | CRBN×GSPT1 | |||||
| Structure |
|
|||||
| Formula | C26H30ClN5O5 |
|||||
| Isosmiles | CNCCOCCC1=C(Cl)C=C(NC(NCC2=CC=C(C(CN3C(C4=O)CCC(N4)=O)=C2)C3=O)=O)C=C1 |
|||||
| PubChem CID | ||||||
| InChI |
InChI=1S/C26H30ClN5O5/c1-28-9-11-37-10-8-17-3-4-19(13-21(17)27)30-26(36)29-14-16-2-5-20-18(12-16)15-32(25(20)35)22-6-7-23(33)31-24(22)34/h2-5,12-13,22,28H,6-11,14-15H2,1H3,(H2,29,30,36)(H,31,33,34)
|
|||||
| InChIKey |
CHFAZLBAAPOQTD-UHFFFAOYSA-N
|
|||||
| Pharmaceutical Properties | Molecule Weight |
528.009 |
Polar area |
128.87 |
||
Complexity |
1156.555939 |
xlogp Value |
2.2012 |
|||
Heavy Count |
37 |
Rot Bonds |
10 |
|||
Hbond acc |
6 |
Hbond Donor |
4 |
|||
Each Antibody-drug Conjugate Related to This Payload
Full Information of The Activity Data of The ADC(s) Related to This Payload
wO2024169913A1 ADC01-01-8 [Investigative]
Revealed Based on the Cell Line Data
| Experiment 1 Reporting the Activity Date of This ADC | [1] | ||||
| Efficacy Data | Half Maximal inhibitory Concentration (lC50) |
0.002829 nM
|
High HER2 expression (HER2+++) | ||
| Method Description |
Cytotoxicity of ADC to BT-474 cells
|
||||
| In Vitro Model | Invasive breast carcinoma | BT-474 cells | CVCL_0179 | ||
| Experiment 2 Reporting the Activity Date of This ADC | [1] | ||||
| Efficacy Data | Half Maximal inhibitory Concentration (lC50) |
0.008852 nM
|
High HER2 expression (HER2+++) | ||
| Method Description |
Cytotoxicity of ADC to SK-BR-3 cells
|
||||
| In Vitro Model | Breast adenocarcinoma | SK-BR-3 cells | CVCL_0033 | ||
| Experiment 3 Reporting the Activity Date of This ADC | [1] | ||||
| Efficacy Data | Half Maximal inhibitory Concentration (lC50) |
0.2212 nM
|
High HER2 expression (HER2+++) | ||
| Method Description |
Cytotoxicity of ADC to NCI-N87 cells
|
||||
| In Vitro Model | Gastric tubular adenocarcinoma | NCI-N87 cells | CVCL_1603 | ||
| Experiment 4 Reporting the Activity Date of This ADC | [1] | ||||
| Efficacy Data | Half Maximal inhibitory Concentration (lC50) |
1.449 nM
|
Low HER2 expression (HER2+) | ||
| Method Description |
Cytotoxicity of ADC to T47D cells
|
||||
| In Vitro Model | Invasive breast carcinoma of no special type | T47D cells | CVCL_0553 | ||
wO2024169913A1 ADC04-09-8 [Investigative]
Revealed Based on the Cell Line Data
| Experiment 1 Reporting the Activity Date of This ADC | [1] | ||||
| Efficacy Data | Half Maximal inhibitory Concentration (lC50) |
0.2235 nM
|
High DLL3 expression (DLL3+++) | ||
| Method Description |
Cytotoxicity of ADC to NCI-H82 cells
|
||||
| In Vitro Model | Lung small cell carcinoma | NCI-H82 cells | CVCL_1591 | ||